Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
about
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismTrends in the development of oral anticoagulants.Anticoagulation Therapy in Patients with Chronic Kidney Disease.A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risksApixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsDabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Rivaroxaban in atrial fibrillation.Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial.Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjectsRole of pharmacogenomics in the management of traditional and novel oral anticoagulantsFuture directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.New oral anticoagulants.Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.Monitoring of direct anticoagulants.Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.The role of apixaban for venous and arterial thromboembolic disease.Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.Implementing the new oral anticoagulants into the hospital formulary.Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.New avenues for anticoagulation in atrial fibrillation.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.Pharmacology of the new target-specific oral anticoagulants.New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients.Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta-analysis.Hepatotoxicity of New Oral Anticoagulants (NOACs).Efficacy and safety of novel anticoagulants compared with established agents.Advances in oral anticoagulants: focus on dabigatran etexilate.Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.
P2860
Q28087447-D675F9C9-4236-4256-8195-6A52388EA400Q33424198-5DEC8366-7D1F-45F5-8FE4-A2D2CCFABD90Q33435357-122436C2-11F4-451B-B559-670CFAE481A2Q33949244-5CE6B70D-BFCD-4257-86D5-A2CD05E6536DQ34285711-0966B797-DE4D-4975-A1A2-A90B28CC7F38Q34638063-1998E136-6B18-4C1B-B19C-3476C5F8DFFFQ36207101-FCC29B7C-A3E2-4601-821C-48B0BD5C60ADQ36336046-F3DD7206-58F8-4BD4-941F-3E90F3228E69Q36402738-5FF0B04F-46B2-41D4-9ED7-9493F1E71E9BQ36729949-623E43EC-0E95-40D3-B78B-DE6B46DCE300Q36848449-B0857889-FDC1-499C-A6BA-29C6C0ABC08EQ37822915-F4472BBD-FADC-42B0-B718-8C378584A7C7Q37831318-D6B26D70-F183-438C-9FA0-1B24F200B966Q37843749-AE1C713E-601E-4FF3-9605-080B0DB0331AQ37848142-AEC2D1F6-43F1-4744-9393-E2964FA6A2EAQ37853075-3DDB97D4-CDE5-46C2-8412-7319F14ED183Q37889269-85128543-1B7B-46E1-AD0D-DF1FF4CDBF91Q37939851-D7D46257-7E63-4C8D-A5E8-61591EFEAD11Q37955199-6DB0F6A5-4B8C-4697-B884-4554709939A3Q38001974-E87CF44D-6D7A-4F65-A434-EE5225A94E0DQ38049617-1D347366-5929-4B67-9AA3-E3BAAF101A07Q38065063-B51E334F-1AD8-4478-B089-A8B7B99A8BE4Q38079779-F8C9F159-D065-4718-A917-8491747B299DQ38087189-079E69E7-9F55-4244-AB68-DFC6438F3CEAQ38101845-B528B9D0-0775-4E47-A8C6-11A4BE268067Q38104314-1247453D-3AA2-4CC1-9B23-A0376C48354BQ38223377-79D0694A-E868-469F-BBF1-413A07EBAF84Q38390896-2C0DA55C-4FDE-4542-A357-6C680754F4E8Q38542198-C7F434A5-0068-4CDA-A619-6AB2A82152B2Q42017822-420BC88F-F815-4E37-92C3-B72AEEA3316BQ42723607-13C022B8-1C2D-44E1-BF75-7E4CD358AAC6Q47694198-108B82C3-6A66-427B-AA95-803E6C19407C
P2860
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Comparative efficacy and safet ...... ical and clinical development.
@en
Comparative efficacy and safet ...... ical and clinical development.
@nl
type
label
Comparative efficacy and safet ...... ical and clinical development.
@en
Comparative efficacy and safet ...... ical and clinical development.
@nl
prefLabel
Comparative efficacy and safet ...... ical and clinical development.
@en
Comparative efficacy and safet ...... ical and clinical development.
@nl
P356
P1476
Comparative efficacy and safet ...... ical and clinical development.
@en
P2093
P304
P356
10.1160/TH09-09-0659
P577
2010-02-02T00:00:00Z